CXCR4 and adrenal cortex carcinoma: A recent publication confirmed high tracer uptake in ACC tumors in CXCR4-directed PET/CT [83], and initial studies of immune checkpoint inhibitors in ACC were heterogeneous, with only few patients benefiting from treatment [84,85,86,87,88].